Microcap Ledger Verrica Pharmaceuticals Inc. $VRCA
Facts as of . Built from SEC filings and our own data. Small caps move fast; check the latest filings.
Snapshot
- Exchange
- Nasdaq Capital Market
- Sector
- Pharmaceutical Preparations
- Headquarters
- West Chester, PA
- Fiscal year end
- December 31
- Shares outstanding
- 17,178,786 [10-Q 2026-08-06]
What the company doesAI summary of filing
Verrica Pharmaceuticals is a therapeutics company developing and commercializing medications for dermatologic diseases, including skin cancers. The company has one FDA-approved commercial product, YCANTH (VP-102), a cantharidin-based topical solution approved in July 2023 for treating molluscum contagiosum in patients aged two and older, which the company launched in the United States in August 2023 with a specialized sales organization of approximately 40 field representatives. The company is also developing YCANTH (VP-102) for common warts, with a Phase 3 program that commenced in late 2025, and is developing VP-315, an oncolytic peptide-based injectable therapy, for basal cell carcinoma treatment, currently in Phase 3 program planning. The company makes money from product sales and milestone and royalty payments from license agreements with Torii Pharmaceutical for Japanese rights and Lytix BioPharma for VP-315 technology. [10-K 2026-03-11]
Financial health
| Period | Revenue | Net income | Operating cash flow | Cash | Filing |
|---|---|---|---|---|---|
| 6 months to Jun 2026 | $10.88M | −$22.84M | −$18.44M | $11.20M | [10-Q 2026-08-06] |
| FY ended Dec 2025 | $35.58M | −$17.90M | −$17.63M | $30.15M | [10-K 2026-03-11] |
| FY ended Dec 2024 | $7.57M | −$76.60M | −$60.93M | $46.33M | [10-K 2026-03-11] |
- Quarterly cash burn
- −$9.22M
- Cash runway Estimate
- ~3.6 months
Capital structure and dilution
| Date | Shares outstanding | Filing |
|---|---|---|
| 2024-10-28 | 45,600,795 | [10-Q 2024-11-05] |
| 2025-03-05 | 91,779,993 | [10-K 2025-03-11] |
| 2025-05-07 | 92,490,993 | [10-Q 2025-05-13] |
| 2025-08-05 | 9,445,768 | [10-Q 2025-08-12] |
| 2025-11-07 | 9,490,035 | [10-Q 2025-11-14] |
| 2026-03-02 | 17,178,786 | [10-K 2026-03-11] |
| 2026-05-05 | 17,178,786 | [10-Q 2026-05-12] |
| 2026-07-31 | 17,178,786 | [10-Q 2026-08-06] |
- Shelf registration
- S-3 filed 2025-12-15; declared effective 2025-12-23 [S-3 2025-12-15]
Listing status
Current status: 2 Form 8-K Item 3.01 filing(s) in the last 24 months, most recent 2025-07-30. Item 3.01 covers delisting notices, failures to meet a listing rule and listing transfers; read the filing for which one.
| Date | Event | Details | Deadline | Filing |
|---|---|---|---|---|
| 2025-07-30 | 8-K Item 3.01 | Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing | — | [8-K 2025-07-30] |
| 2025-01-30 | 8-K Item 3.01 | Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing | — | [8-K 2025-01-30] |
Who owns it
| Date | Insider | Type | Shares | Price | Filing |
|---|---|---|---|---|---|
| 2026-08-18 | Rosenberg Noah L. | buy | 2,030 | $4.92 | [4 2026-08-18] |
| 2026-08-18 | Kirby John J. | buy | 5,000 | $4.93 | [4 2026-08-18] |
| 2026-08-17 | Zawitz David | buy | 6,000 | $4.98 | [4 2026-08-18] |
| 2026-08-17 | Rieger Jayson | buy | 5,000 | $4.91 | [4 2026-08-18] |
| 2026-08-17 | Rosenberg Noah L. | buy | 4,200 | $4.91 | [4 2026-08-18] |
| 2026-08-14 | Rieger Jayson | buy | 20,000 | $5.06 | [4 2026-08-18] |
Catalysts and calendar
| Date | Type | Title |
|---|---|---|
| 2026-08-06 | 10-Q | Quarterly report |
| 2026-08-06 | 8-K | Results of operations |
| 2026-06-09 | 8-K | Director or officer change; Shareholder vote results |
| 2026-05-12 | 10-Q | Quarterly report |
| 2026-05-12 | 8-K | Results of operations |
| 2026-04-20 | DEF 14A | Proxy statement |
| 2026-03-11 | 10-K | Annual report |
| 2026-03-11 | 8-K | Results of operations |
| 2026-02-17 | 13G/A | Beneficial ownership report (5%+ holder) |
| 2026-01-29 | 13G/A | Beneficial ownership report (5%+ holder) |
| 2025-12-30 | 13D/A | Beneficial ownership report (5%+ holder) |
| 2025-12-30 | 8-K | Director or officer change |
Alerts for $VRCA
Email me when Verrica Pharmaceuticals Inc. files an offering, gets a deficiency notice, or moves sharply.
Facts as of . Small caps move fast; check the latest filings.